French National Database of Rare Dermatological Cancers (CARADERM)

University Hospital, Lille

Status

Enrolling

Conditions

Adnexal Tumor of Skin

Advanced Basal Cell Carcinoma Requiring Systemic Treatment

Merkel Cell Carcinoma

Study type

Observational

Funder types

Other

Identifiers

NCT03210935

NI_2014_60

Details and patient eligibility

About

Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, and cutaneous adnexal carcinomas are 3 types of rare skin cancers for which much remains unknown in terms of natural behavior, prognosis, treatment and outcomes.

CARADERM is a French prospective national cohort enrolling patients with either one of these 3 tumor types, whose objectives are :

to provide epidemiological, clinical and socio-economic characteristics of patients
to identify new clinical or epidemiological prognostic factors for these rare cancers
to evaluate the impact of various treatments on outcomes

Full description

CARADERM is a French national multidisciplinary project which will prospectively enroll from 37 French centers any patient presenting with Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment or cutaneous adnexal carcinoma.

A structured and centralized database of clinical monitoring of patients will be established. Information captured will include clinical constitutional factors, factors linked to primary carcinoma, factors linked to lymph node involvement, "American Joint Committee on Cancer" (AJCC) stage at inclusion, recurrence patterns, therapeutic interventions (medical, surgical, radiotherapy and palliative strategies) with evaluation of response, date of death, date of latest news.

Enrollment

9,000 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with histologically confirmed Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma

Exclusion criteria